0 enhancer region (ER) of the thymidylate synthase (TS) gene, a variable number of tandem repeats of a 28 bp sequence (2R/3R) and a further G4C single nucleotide substitution within the repeats, result in genotypes with 0-5 functional upstream stimulatory factor (USF) E-box consensus elements. However, the relationship between these polymorphisms, regulation of TS expression and patient response to fluoropyrimidine treatment has been inconsistent. In this study, seven possible TSER allele configurations showed similar patterns of luciferase gene expression regardless of cell type or USF-1 content, with no significant difference in promoter activity between the wild-type 2RGC and 3RGGC (1.40 ± 0.37 vs 1.43 ± 0.32, P ¼ 0.90), whereas the minor alleles, 2RCC and 3RGCC, were significantly reduced (0.84 ± 0.17, P ¼ 0.01) and increased (3.19±0.72, P ¼ 0.001) respectively. Patient plasma levels of 2 0 -deoxyuridine, a surrogate marker of TS activity, were significantly different between genotypes (Po0.001) and inversely related to luciferase activity (P ¼ 0.02) but not to the absolute number of functional repeated elements (P ¼ 0.16), suggesting that the position, rather than the number of functional USF E-box repeats in the TSER, is responsible for determining gene expression in vitro and TS activity in vivo.
Introduction
Thymidylate synthase (TS) catalyses the reductive methylation of 2 0 -deoxyuridine 5 0 -monophosphate to 2 0 -deoxythymidine 5 0 -monophosphate in the sole de novo pathway for production of 2 0 -deoxythymidine 5 0 -triphosphate required for DNA synthesis. This vital role makes TS an important target for cancer chemotherapeutics, and drugs such as capecitabine and 5-fluorouracil (5-FU) are able to arrest the growth of rapidly dividing cells by selectively inhibiting the activity of TS. The subsequent decrease in production of 2 0 -deoxythymidine 5 0 -triphosphate results in the accumulation of its precursor, 2 0 -deoxyuridine 5 0 -monophosphate, which is then catabolized to 2 0 -deoxyuridine (dUrd) and effluxed from the cell into the circulation. 1 Therefore plasma levels of dUrd represent a surrogate marker of TS inhibition and have been used to monitor individual 5-FU pharmacodynamics in cancer patients.
Expression of TS is determined in part by polymorphic features in the 5
0 -upstream promoter/enhancer region (ER) of the TS gene, TYMS, that influence transcription and translation of the mRNA. The first of these is a variable number of tandem repeats (VNTR) polymorphism consisting of multiple repeats of a 28 bp sequence. 4 Although there have been reports of up to nine copies of the VNTR in certain populations, [5] [6] [7] the majority of TYMS alleles contain only two or three repeats, and have been designated 2R or 3R, respectively. The 3R is most common, with an allele frequency of 0.6 in Caucasian and 0.8 in Chinese and Japanese populations. 8 In vitro studies have shown that translation is up to four times more efficient from an RNA construct containing three repeats compared with two repeats, 5, 9 and cancer tissues with a 3R/3R genotype contain significantly greater TS protein than those with a 2R/3R genotype. 9, 10 Each repeat contains a putative E-box binding site (CACTTG) for upstream stimulatory factors (USF-1/USF-2), which is only functional when a guanine (G) is present in the last nucleotide position. The last repeat of both the 2R and 3R wild-type alleles normally contains a cytosine (C) in this position (2RGC and 3RGGC respectively), whereby the binding site for USF is presumably abolished. Polymorphisms (G4C and C4G) have previously been identified in the second repeat of the 3R 11 (3RGCC) and the last repeat of the 2R 12 (2RGG), and most recently, by our group and another concurrently, in the first repeat of the 2R 13, 14 (2RCC). The 3RGCC allele has been well studied and shown to account for 56 and 37% of all 3R alleles in Caucasians and Asians respectively. 11 In contrast, only a single study has reported the identification of 2RGG in a Japanese cohort, and after the authors showed no functional difference between it and 2RGC, no further genotyping was conducted. 12 The frequency of the newest allele, 2RCC, was found to be 3-4% in two separate Caucasian studies. 13, 14 This polymorphism would effectively abolish the only USF E-box consensus sequence in the promoter region of the 2R allele, and according to current theories on the regulation of the TYMS gene, result in severe TS deficiency with implications for efficacy and toxicity of therapy with commonly used fluorouracil-based therapy regimes. So far no homozygous 2RCC individual has been identified, and little is known about the effects of this new polymorphism in humans.
There have been at least six published analyses of the transcriptional activity associated with the repeats in the ER of TYMS, utilizing various cDNA constructs, assay systems and cell lines [4] [5] [6] 11, 12, 15 (Table 1) . However, only one of these investigations included 2RCC 11 and none have compared all major 2R and 3R polymorphic alleles in a single study. In addition, constructs of 2RCG and 3RGGG have never been analysed. We sought to further characterize the activity of 2RCC with respect to other known polymorphisms in the promotor region of TYMS by carrying out a comprehensive in vitro analysis of all constructs in a single set of experiements using two colon cancer cell lines that show differential USF-1 isoform expression, WiDr and HCT-116, in addition to the commonly used HeLa cervical cancer cell line. The results were then used to predict TS activity and compared with plasma levels of dUrd in a series of colorectal cancer patients before 5-FU treatment.
Materials and methods

Patient cohort
A subset of 29 samples from patients (aged 59 ± 10 years, 18 men/11 women) from a previous study were available for analysis. All had a recent diagnosis of colorectal cancer stage B (n ¼ 5) or C (n ¼ 24), with the Eastern Cooperative Oncology Group performance status 0, and no other significant medical illnesses. All had normal haematological (Hb4100 g l À1 , white blood cells44.0 Â 10 9 per litre, Table 1 Relative promoter activities from previous studies of TSER polymorphisms Kaneda et al. 4 Horie et al. 5 Luo et al. 6 
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Blood samples
Baseline blood samples were collected on the day (time range 0845-1600 hours) before 5-FU/LV administration, for genotyping (EDTA, 2 Â 4 ml) and dUrd measurements (lithium heparin, 5 ml). Post-treatment blood samples were again collected 60 min after 5-FU/LV administration for dUrd measurements. Plasma was isolated by centrifugation at 1450 g and stored at À80 1C until analysis. Non-treated blood plasma purchased from the Red Cross was dialysed with cellulose membrane tubing (molecular cut-off size of p1200) overnight to remove endogenous dUrd and used for standards and controls for dUrd assays.
TSER genotyping
All genotyping was performed by polymerase chain reaction (PCR)-restriction fragment length polymorphism as previously described. 13, 16 Initial reactions were performed using Red Hot DNA polymerase (ABgene, Surrey, UK) and products were electrophoresed to distinguish between the 2R (210 bp) and the 3R (238 bp) TYMS alleles. The reaction was then repeated and the products were digested with HaeIII to detect the G4C SNP. All PCR analyses were performed in a microtube thermocycler (Corbett Research, Sydney, Australia), all oligonucleotide primers were synthesized by GeneWorks (Adelaide, Australia) and all products were electrophoresed through Ultrapure Agarose-1000 high-resolution gel (Invitrogen, Carlsbad, CA, USA) in 1 Â TBE buffer and visualized with ethidium bromide to identify genotypes by restriction fragment banding patterns.
Cell culture
Colon cancer cell lines, WiDr and HCT 116, and cervical cell line, HeLa, were obtained from the American Type Culture Collection (Manassas, VA, USA). All cells were cultured in Dulbecco's modified Eagle's medium (Lonza, Walkersville, MD, USA) supplemented with 10% fetal bovine serum (Invitrogen) maintained at 37 1C in a humidified atmosphere of 5% CO 2 /95% air.
Cloning and plasmid construction
Polymerase chain reaction using KOD XL DNA polymerase (Novagen, Merck, Darmstadt, Germany) was used to amplify the 2R and 3R fragments from a pool of human genomic DNA previously genotyped 13 using specific primers (forward primer: 5 0 -ccgctcgagcggcccgtggctcctgcgtttccccctgg-3 0 ; reverse primer: (5 0 -cccaagcttggggctccgagccggccacaggcatgg-3 0 ) incorporating XhoI and HindIII restriction sites respectively (bold and underlined). The 2RCG, 3RGGC and 3RCCC sequences with similar restriction sites above were synthesized (GenScript USA Inc., Piscataway, NJ, USA) into the pUC57 subcloning vector. All amplified and synthesized DNA sequences were subsequently digested with XhoI and HindIII and ligated in the matching sites of the promoterless pGL2-Basic vector (Promega, Madison, WI, USA). All resulting clones were sequenced by Australian Genome Research Facility Ltd (Brisbane, Queensland, Australia).
Cell transfection and luciferase assay Cells were plated into 24-well cell culture plates at 80 000 per well on day 1. The following day, each well was transfected with 800 ng of pGL2 vector containing the alternate TYMS promoter region polymorphisms in addition to 20 ng of pRL-TK control (Promega) vector to normalize transfection efficiency using Lipofectamine 2000 (Invitrogen) according to the manufacturers' instructions. Cells were lysed with passive lysis buffer (Promega) 24 h after transfection and Firefly luciferase and Renilla luciferase activities were measured using the dual luciferase assay system (Promega) as per the manufacturer's instructions using the Synergy 2 SL Luminescence Microplate Reader (BioTek USA, Winooski, VT, USA). Activity of the reporter gene was normalized to Renilla luciferase activity and expressed as a percentage of the 1RC construct. The experiments were performed independently on four separate occasions, each in triplicate or quadruplicate.
Cell lysis and Western blot
Protein was isolated from cells using NDE (1% NP40, 0.4% deoxycholate, 66 mM EDTA, 10 mM Tris-Cl, pH 7.4) lysis buffer. Equivalent protein amounts were reduced with 50 mM DTT and 1 Â LDS and resolved on a 8.8% Bis-Tris acrylamide gel before transfer to nitrocellulose membrane. USF-1 antibody (Abnova, Jhongli City, Taiwan) and glyceraldehyde-3-phosphate dehydrogenase (SC-25778; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) antibodies were incubated in 5% skim milk powder dissolved in TBS-T, detected by chemiluminescence and visualized using the LAS4000 system (Fujifilm Corporation, Tokyo, Japan).
Plasma dUrd measurement
Plasma dUrd levels were measured using a previously validated high-performance liquid chromatograph-mass spectrometry method.
3 A 1 ml plasma sample containing an internal standard 5-iodo-2 0 -deoxyuridine (IdUrd; SigmaAldrich, New South Wales, Australia) was extracted using strong anion exchange solid-phase extraction cartridges, SAX-SPE (4 ml, 200 mg; Grace Davison Discovery Science, New South Wales, Australia) followed by HPLC separation through Waters Atlantis dC 18 3 mm, 150 mm Â 2.1 mm analytical column (Waters, Sydney, Australia) coupled with a 1 mm Opti-Guard C18 guard column (Choice Analytical Pty Ltd, New South Wales, Australia) and atmospheric pressure chemical ionization mass spectrometry detection (APCI-MS) in a selected ion monitoring mode (Shimadzu LCMS-2010EV; Shimadzu Scientific Instruments (Oceania) Pty Ltd., New South Wales, Australia). The ionization was best optimized in negative ion mode of the dominant format adduct [M þ HCOO]À at m/z 273 for dUrd and m/z 399 for IdUrd. Retention times for dUrd and IdUrd were 4.5 and 12.5 min respectively. The MS data were analysed using software LCMS 2010EV lab solutions V 3.5 (Shimadzu Scientific Instruments (Oceania) Pty. Ltd.). Peak area ratio of dUrd/IdUrd was used for regression analysis of the calibration curve, which was linear from 5 to 400 nM. The average recovery was 90.8 and 82.9% for dUrd and IdUrd respectively. The limit of quantitation was 5 nM with coefficient of variation o15% and inter-day and intra-day coefficients of variation for the assay ranged from 0.5 to 12%.
Statistical analysis
Differences in expression between individual TSER promoter constructs, and changes in dUrd plasma levels after administration of 5-FU, were all analysed by two-tailed Student's t-tests (unpaired and paired). Differences between baseline dUrd plasma levels classified by TYMS genotypes were analysed by one-way analysis of variance for individual genotypes or by ordinal multinomial logistic regression when genotypes were grouped. All analysis were performed using Statistica version 6.0 (StatSoft, Tulsa, OK, USA) and considered statistically significant when P-value was o0.05.
Results
Functional analysis of TSER polymorphisms in vitro
Reporter constructs containing two or three tandem repeat TSER sequences and associated G4C polymorphisms, as indicated in Figure 1 , were transfected into three cell lines.
Two colon cancer lines, WiDr and HCT116, were selected on the basis of their differential USF-1 expression; WiDr expresses both isoforms of the protein whereas HCT116 expresses only the smaller isoform (Figure 2, inset) . HeLa cells also express only the smaller USF-1 isoform and were used as a comparison as they have been the most commonly used cell line for these experiments ( Table 1) .
As shown in Figure 2 , a similar pattern of relative luciferase expression was observed in all three cell lines, with 2RCC providing the least expression and 3RGCC consistently giving the highest expression. Analysis of expression activity within the 2R constructs alone for each cell line saw slight variations in activity. For the WiDr and HeLa the trend for activity followed 2RCCo2RGGo2RC-Go2RGC. HCT116 had a minor difference such the activity followed the trend of 2RCCo2RGGo2RGCo2RCG. Analysis of expression within the 3R constructs alone for all three cells lines consistently showed the trend of activity 3RGGCo3RCCCo3RGCC. In comparing the 3R to the 2R constructs across all cell lines, only in HCT116 did all 3R constructs produce greater activity than all of the 2R constructs, whereas in both WiDr and HeLa, only the 3RGCC construct showed any significant increase from the highest expressing 2R construct. When the wild-type 2RGC was directly compared with the wild-type 3RGGC, results were equivocal: 3RGGC expression was higher in HCT116, lower in WiDr and equal in HeLa.
As anticipated, the 2RCC promoter, which contains two non-functional USF E-box transcription factor elements, showed the least amount of promoter activity in all cell lines. Surprisingly, the 2RGG construct, containing two tandem copies of a functional sequence, did not show significantly greater activity. Only when a functional sequence was juxtaposed to a non-functional sequence was there any significant increase in promoter activity, and for WiDr this was significantly greater for the 2RGC construct, representing the wild-type 2R allele of TYMS. Although the 2RCG construct was assessed for completeness, this has not yet been identified in vivo.
There was also no significant difference in promoter activity between the most common two and three repeat promoter sequences, 2RGC and 3RGGC, despite the presence of an additional functional E-box in the 3RGGC. Curiously, the removal of all functional E-box sequences in the manufactured 3RCCC did not decrease promoter activity, but actually enhanced it in the two colon cancer cell lines. Moreover, counterintuitively, the minor allele, 3RGCC, with only one active E-box, consistently showed the highest promoter activity in all cell lines when compared with all the other constructs.
Because the luciferase results from all three cell lines were similar, these were averaged and are presented in Table 2 . Of the promoter sequences that have been identified in vivo, the more common 2RGC and 3RGGC sequences were not significantly different in terms of promoter activity (1.40 ± 0.37 vs 1.43 ± 0.32, P ¼ 0.90), whereas the two minor alleles, 2RCC and 3RGCC, were significantly reduced (0.84 ± 0.17, P ¼ 0.01) and increased (3.19 ± 0.72, P ¼ 0.001) respectively. The promoter constructs were classified into three groups based on mean luciferase activities of 1.0, 1.5 and 3.0.
Effects of TSER polymorphisms on plasma dUrd levels in vivo
Baseline plasma levels of dUrd were measured in 29 colorectal cancer patients before their first ever dose of 5-FU/LV. These baseline levels varied widely between individuals, ranging from 6 to 108 nM. There was no correlation between these levels and patient demographics of age, gender or stage of disease (data not shown). When plasma levels were tested again 60 min after administration of 5-FU/LV, the dUrd levels increased significantly to 52-385 nM (n ¼ 25; paired t-test Po0.00001; Figure 3) , representing a median increase of 197% (range: À4 to 5099%). This expected increase in plasma dUrd in response to 5-FU-induced TS inhibition was observed in all patients except for one. This patient had the highest baseline level of dUrd (108 nM) and it remained similar after administration of 5-FU (103 nM). Baseline dUrd plasma levels were found to be significantly different between TYMS genotypes (analysis of variance d.f. ¼ 7, Po0.001). When the genotypes were ordered according to increasing levels of plasma dUrd, a pattern emerged whereby the genotypes corresponding to promoter combinations with the highest predicted luciferase activities (based on sum of mean luciferase values for each allele from Table 2 ) had the lowest plasma levels of dUrd, and those with lower promoter activity had much higher levels of plasma dUrd (Table 3 ). In contrast, there did not appear to be any pattern of genotypes based solely on the number of functional USF binding sites they contained. When the genotypes were grouped according to either of these parameters, plasma dUrd levels were found to be significantly inversely related to promoter activity as predicted by the sum of the luciferase activity (ordinal logistic regression, P ¼ 0.02) but not significantly associated with the number of functional TSER repeats (P ¼ 0.16). Furthermore, the percentage change in dUrd levels at 60 min relative to baseline was not significantly associated with genotype (analysis of variance, n ¼ 25, d.f. ¼ 6, P ¼ 0.28).
Discussion
Our in vitro studies indicated that the wild-type 2R (2RGC) and 3R (3RGGC) alleles containing one or two active E-box repeats, respectively, had similar promoter activities. However, counterintuitively, the minor 3RGCC allele with only one active E-Box repeat had significantly increased activity compared with both wild-type 2R and 3R alleles. This result is contrary to the majority of other studies with the exception of that of Horie et al., 5 which also confirmed that the polymorphic 3RGCC has greater in vitro promoter activity compared with the wild-type 3RGGC. The latter investigation concluded that at least one repeated sequence and its complementary sequence were necessary for the efficient expression of the TYMS gene. To ensure the current data were truly reflective of the assigned genotypes, we resequenced all constructs to confirm that the polymorphic repeats were correct (Supplementary Information). An analysis of the varying amount of upstream sequence included in other studies may explain our findings. As shown in Figure 4 , the region upstream of the TS VNTR contains additional regulatory regions, both positive and negative. In particular, the CACCC box (CCACACCC), which binds zinc-finger transcription factors of the Kruppel family such as SP1, and an additional sequence homologous to the SP1 binding site of the mouse TS gene have been shown to be necessary for efficient promoter activity and these are interspaced by two negative regulatory regions. 17 The two studies that have shown increased promoter activity using a 3RGCC allele, ours and that of Horie et al., 5 were unique in that both used similar constructs, containing sequence that included only one negative regulatory region and all or part of the CACCC box. It is likely that this influenced the transcription/translation of the reporter gene and subsequent activity readout. Curiously, analyses that included both or neither of the negative regulators all indicated that the wild-type 3RGGC had the highest promoter activity. 11, 12, 15 Despite these discrepancies, our study results are internally consistent in that promoter activity was always more efficient when a functional E-box is teamed with one that is non-functional, and externally consistent with other studies that have indicated that the presence of additional functional sequences (that is, 4RGGGC, 5RGGGGC) does not improve promoter activity. 4, 6 Taken together, these studies suggest that it is not the number of functional sequences, as previously hypothesized, but their position within the promoter, that determines TS gene activity.
The association between TSER genotype and promoter activity in vitro was corroborated by analysis of dUrd plasma levels in vivo. The latter were found to be significantly associated with genotype when ranked according to luciferase activity, but not when analysed by the absolute number of functional USF binding elements. Consistent with this, the patient with the highest baseline level of plasma dUrd was also the only 2RCC/3RGGC genotype, and would be expected to have the lowest TYMS promoter activity as predicted by our luciferase assays. Strangely, this patient was also the only one who did not show increased plasma dUrd after administration of 5-FU/LV, and we can offer no explanation for this. All other patients showed a significant but variable increase in plasma dUrd levels after 5-FU treatment, consistent with other reports. 2, 3, 18 This study further indicates that this wide range of individual response to 5-FU is not attributable to TS genotype, revealing the importance of other enzymes in the folate metabolism pathway and suggesting that inhibition of TS enzymatic activity is complete in the presence of high concentrations of 5-FU, regardless of baseline TS activity. It could be argued that the lack of correlation between TSER genotype and changes in dUrd levels in response to 5-FU may simply be a reflection of the 60 min sampling time used in this study. Indeed, other clinical trials have used much longer time points, beginning at 24 h after treatment, and showed elevated dUrd levels that remained stable for up to 4 days after bolus 5-FU/LV, 2 8 days following continuous infusion of 5-FU, 2 and even longer following capecitabine treatment. 3, 18 In contrast, in vitro assays of TS activity in lymphocyte cell lines have indicated that the reaction is only linear for up to 2 h. 19 In our own preliminary studies on colorectal cancer patients, plasma levels of 5-FU peaked at 10 min following bolus injection before being quickly cleared from the circulation and then barely detectable in most individuals by 60 min (data not shown). Any dUrd levels tested before this time may be confounded by individual differences in cellular drug influx or efficiency of folate metabolism, whereas samples after this time may be affected by dUrd clearance rates. Thus we felt that 60 min was the earliest and best time point for reliable studies. Further investigations into the relationship between plasma 5-FU clearance and dUrd accumulation are warranted in this regard.
There have been numerous attempts to link TSER polymorphisms in tumour tissues and/or blood samples with clinical outcomes in cancer patients receiving pyrimidine anti-metabolite treatment, and the details of these results have been summarized in a recent report by Mauritz et al.
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Conclusions have been largely inconsistent, perhaps owing in part to the extent of genotyping performed (that is, VNTR only vs VNTR þ 3RG4C vs VNTR þ 3RG4C þ 2RG4C) and the many different categorizations used to combine the VNTR and G4C polymorphisms. These classification systems have all been based on the results of promoter activity assays in vitro which have consistently shown a hierarchal pattern of increasing activity from 2R43RGCC43RGGC (Table 1) . These experiments in themselves have differed by sequences contained in the promoter constructs, the cell lines used for gene expression and the actual reporter assay used. However, no one has previously attempted to associate any of these in vitro results with TS activity in vivo. Our study results suggest that the polymorphic 3RGCC, and not the wild-type 3RGGC as previously thought, has the highest promoter activity. However, TS activity in vivo may inevitably be swamped by the large doses of 5-FU administered to cancer patients, providing the ultimate explanation for the lack of consistent correlation between TSER gene polymorphisms and clinical outcomes. Unfortunately, our study is limited by its retrospective nature and that the number of patients experiencing chemotherapy-related toxicity were not sufficient to allow further analysis between genotype and dUrd levels with clinical outcomes. Plasma analysis of dUrd levels should be included in future TS genotyping studies to substantiate the extent of TS inhibition during 5-FU treatment. 
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